Last Updated: November 17, 2026

Claims for Patent: 12,043,626

« Back to Dashboard


Summary for Patent: 12,043,626
Title:Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
Abstract:Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of formula (I), pharmaceutical compositions comprising the same, and methods of treating, preventing, and managing various disorders using the compositions provided herein.
Inventor(s):Sibao Chen, Christopher G. F. COOPER, Baudouin Gerard, Joshua Courtney Horan, Jason T. KROPP, Benjamin Stephen LANE, David James Pearson
Assignee: Nuvalent Inc
Application Number:US17/957,725
Patent Claims: 1. A solid form comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein: (a) the solid form comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 10.7, 15.0, and 21.2° 2θ±0.2° 2θ; (b) the solid form comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 8.6, 14.0, and 20.8° 2θ±0.2° 2θ; (c) the solid form comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 13.4, 19.5, and 20.9° 2θ±0.2° 2θ; (d) the solid form comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 12.1, 12.7, and 18.4° 2θ±0.2° 2θ; (e) the solid form comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 10.5, 10.8, and 21.9° 2θ±0.2° 2θ; (f) the solid form comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 8.6, 18.7, and 20.5° 2θ±0.2° 2θ; (g) the solid form comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 12.5, 13.4, and 14.6° 2θ±0.2° 2θ; (h) the solid form comprises a besylate salt of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 15.0, 17.9 and 23.0° 2θ±0.2° 2θ; or (i) the solid form comprises a phosphate salt of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 10.8, 18.5, and 24.8° 2θ±0.2° 2θ.

2. The solid form of claim 1, which comprises a free base of a compound formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 10.7, 15.0, and 21.2° 2θ±0.2° 2θ.

3. The solid form of claim 2, wherein the XRPD pattern further comprises peaks at 17.4 and 21.3° 2θ±0.2° 2θ.

4. The solid form of claim 3, wherein the XRPD pattern further comprises peaks at 12.0, 12.2, and 13.9° 2θ±0.2° 2θ.

5. The solid form of claim 2, which is characterized by an XRPD pattern that matches the XRPD pattern depicted in FIG. 1 .

6. The solid form of claim 2, which exhibits an endothermic event, as characterized by DSC, with an onset temperature at about 265° C.±2° C. and/or a peak temperature at 267° C.±2° C.

7. The solid form of claim 2, characterized by a DSC thermogram that matches the DSC thermogram depicted in FIG. 3 .

8. The solid form of claim 2, which exhibits a weight increase of about 0.25% when subjected to an increase in relative humidity from about 0 to about 90% relative humidity.

9. The solid form of claim 2, having approximately unit cell dimensions of: a=8.4 Å, b=8.4 Å, c=14.9 Å, α=90°, β=106°, and γ=90°.

10. The solid form of claim 1, which comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 8.6, 14.0, and 20.8° 2θ±0.2° 2θ.

11. The solid form of claim 10, which exhibits an endothermic event, as characterized by DSC, with an onset temperature at 96° C.±2° C.; and/or an exothermic event, as characterized by DSC, with an onset temperature at 169° C.±2° C.

12. The solid form of claim 1, which comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 13.4, 19.5, and 20.9° 2θ±0.2° 2θ.

13. The solid form of claim 12, which exhibits an exothermic event, as characterized by DSC, with an onset temperature at 168° C.±2° C.

14. The solid form of claim 1, which comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 12.1, 12.7, and 18.4° 2θ±0.2° 2θ.

15. The solid form of claim 14, which exhibits an endothermic event, as characterized by DSC, with an onset temperature at 135° C.±2° C.

16. The solid form of claim 1, which comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 10.5, 10.8, and 21.9° 2θ±0.2° 2θ.

17. The solid form of claim 1, which comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Ka radiation, comprising peaks at 8.6, 18.7, and 20.5° 2θ±0.2° 2θ.

18. The solid form of claim 17, which exhibits an endothermic event, as characterized by DSC, with an onset temperature at 126° C.±2° C.

19. The solid form of claim 1, which comprises a free base of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 12.5, 13.4, and 14.6° 2θ±0.2° 2θ.

20. The solid form of claim 19, having approximately unit cell dimensions of: a=8.0 Å, b=14.8 Å, c=18.0 Å, α=90°, β=90°, and γ=90°.

21. The solid form of claim 1, which comprises a besylate salt of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 15.0, 17.9 and 23.0° 2θ±0.2° 2θ.

22. The solid form of claim 21, which exhibits an endothermic event, as characterized by DSC, with an onset temperature at 128° C.±2° C. and/or a peak temperature at 136° C.±2° C.

23. The solid form of claim 1, which comprises a phosphate salt of a compound of formula (I), and is characterized by an XRPD pattern, when measured using Cu Kα radiation, comprising peaks at 10.8, 18.5, and 24.8° 2θ±0.2° 2θ.

24. A pharmaceutical composition comprising the solid form of claim 1 and a pharmaceutically acceptable excipient.

25. The solid form of claim 19, wherein the XRPD pattern further comprises peaks at 20.9 and 22.8° 2θ±0.2° 2θ.

26. The solid form of claim 25, wherein the XRPD pattern further comprises peals at 11.4 and 15.8° 2θ±0.2° 2θ.

27. The solid form of claim 19, which is characterized by an XRPD pattern that matches the XRPD pattern depicted in FIG. 19 .

28. A pharmaceutical composition comprising the solid form of claim 2 and a pharmaceutically acceptable excipient.

29. A pharmaceutical composition comprising the solid form of claim 10 and a pharmaceutically acceptable excipient.

30. A pharmaceutical composition comprising the solid form of claim 12 and a pharmaceutically acceptable excipient.

31. A pharmaceutical composition comprising the solid form of claim 14 and a pharmaceutically acceptable excipient.

32. A pharmaceutical composition comprising the solid form of claim 16 and a pharmaceutically acceptable excipient.

33. A pharmaceutical composition comprising the solid form of claim 17 and a pharmaceutically acceptable excipient.

34. A pharmaceutical composition comprising the solid form of claim 19 and a pharmaceutically acceptable excipient.

35. A pharmaceutical composition comprising the solid form of claim 21 and a pharmaceutically acceptable excipient.

36. A pharmaceutical composition comprising the solid form of claim 23 and a pharmaceutically acceptable excipient.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.